INTRODUCTION

A new lineage of the SARS-CoV-2 virus named B.1.1.7 was identified in the United Kingdom in December 2020. Since then, B.1.1.7 variant of concern (VOC) has been increasing in prevalence across Europe. The B.1.1.7 variant is characterized by several genetic mutations (including N501Y substitution) in the immunodominant spike protein including the receptor-binding domain. Prior investigations have suggested that B.1.1.7 is more transmissible. However, results regarding the effects of B.1.1.7 on pneumonia severity are inconsistent. While Dan Frampton and colleagues reported that disease severity and clinical outcomes between patients with B.1.1.7 and non-B.1.1.7 infections were similar, three other studies have shown that lineage B.1.1.7 was linked with increased mortality. CT plays an essential role in the assessment of disease severity as well as in the evaluation of the temporal changes of the extent of pneumonia. However, since not all patients with COVID-19 have complicated disease, chest CT should be reserved for patients with specific clinical indications, as recommended by the American College of Radiology. During the early exudative phase of COVID-19 pneumonia, ground-glass opacity (GGO) in the lower lobes is the main
characteristic CT abnormality progressing into consolidation at later stages of the disease course.\textsuperscript{5,8,9} To the best of our knowledge, no prior studies have investigated the differences in quantitative metrics and radiomorphological appearance of pneumonia between B.1.1.7 and non-B.1.1.7 SARS-CoV-2 infections.

We aimed to investigate the differences in demographic, clinical, and laboratory data between B.1.1.7 and non-B.1.1.7 SARS-CoV-2 infections. Moreover, we assessed whether there was a difference in CT-derived quantitative measures between the two lineages. In a secondary analysis, we aimed to determine the age-specific differences in B.1.1.7 and non-B.1.1.7 SARS-CoV-2 infections. In addition, we sought to investigate the clinical outcomes in the patient groups.

METHODS AND MATERIALS

Study design and setting

This analysis included consecutive patients with positive reverse transcription polymerase chain reaction (RT-PCR) result for SARS-CoV-2 who underwent non-contrast chest-CT between September 1–November 13, 2020 (500 non-B.1.1.7 cases) and March 1–March 18, 2021 (500 B.1.1.7 cases). The only exclusion criteria was missing clinical data. These date intervals were selected due to the dominance of non-B.1.1.7 and B.1.1.7 variants. A PCR specific for N501Y mutation of SARS-CoV-2 spike protein gene (Omixon Ltd, Budapest) revealed that during March 1–March 18, 2021 all the patients were infected with the B.1.1.7 variants. A retrospective analysis of 150 samples stored from the period between September 1 and November 13, 2020 indicated that N501Y mutation was absent. The clinical trial protocol was approved by the Ethics Committee of our University (SE RKEB: 256/2020).

Clinical severity and definitions

Clinical severity was graded according to the clinical progression scale of the World Health Organization (WHO).\textsuperscript{10} The scale provides a measure of illness severity across a range from 0 (not infected) to 10 (dead). Based on the WHO score, the patients were classified into four categories according to their outcome: (a) mild disease included asymptomatic or symptomatic cases without the need for in-hospital treatment; (b) moderate disease was defined as hospitalized patients with or without oxygen therapy by mask or nasal prongs; (c) severe disease included hospitalized patients who needed oxygen by non-invasive ventilation or high flow, intubation, mechanical ventilation, vaso-pressor and/or extracorporeal membrane oxygenation and (d) death during in-hospital stay.

Potential confounders included age, sex, body mass index (BMI), hypertension, diabetes mellitus, hyperlipidemia, smoking status, history of chronic lung disease (including asthma, chronic obstructive pulmonary disease, and/or obstructive sleep apnea), heart failure, myocardial infarction, chronic kidney disease (defined as estimated glomerular filtration rate of less than 60 ml/min/1.73 m$^2$) and immunodeficiency (defined as the history of cancer, organ transplantation and/or patients on disease-modifying antirheumatic drugs or glucocorticoids before hospital admission). Self-reported duration and characteristics of symptoms were also collected. Serum laboratory values were obtained at hospital admission.

Scan protocol and image reconstruction

Non-contrast enhanced chest-CT scans were acquired using a 128-slice CT scanner (Philips Incisive, Philips Healthcare, Best, The Netherlands) in supine position during an inspiratory breath-hold. The CT acquisition protocol included a peak tube voltage of 120 kV, automatic tube current modulation (300–500 mAs), and slice thickness of 1 mm, reconstruction increment 0.85 with a collimation of 64 × 0.625. Infection control and protection were taken into account in all cases. Images were reconstructed using standard lung filters. For patients with serial chest-CT examinations, only admission scans were included in the analysis.

CT image analysis

Standard lung window [width of 1500 Hounsfield unit (HU) and level of −400 HU] was used for image analysis. Lung abnormalities including GGO, consolidation, and pleural effusion were quantified with a deep-learning research software (LungQuant v. 1.0, Cedars-Sinai Medical Center, Los Angeles, CA).\textsuperscript{11} First GGO and high-opacities (comprising consolidation and pleural effusion) were segmented using convolutional Long Short-Term Memory (ConvLSTM) network. The acquired lesion masks were then edited when necessary to differentiate consolidation from pleural effusion with semi-automated brush-like tool; the boundaries of which were delimited by a region-growing algorithm. Adaptive thresholds were used, defined by a fixed window around the attenuation of the pixel clicked by the operator. Lobe segmentation was computed using the pulmonary mask and a second deep-learning model trained with the Lung Tissue Research Consortium data set. The right lung was divided into upper, middle and lower lobes by the horizontal and oblique fissures and the left lung was divided into upper and lower lobes by the oblique fissure.

GGO was defined as hazy opacities that do not obscure the underlying bronchial or vascular structures, consolidation as opacification obscuring the underlying bronchial and vascular structures and pleural effusion as a fluid collection in the pleural cavity. Chronic lung abnormalities such as emphysema or fibrosis were excluded from segmentation. Volumes of lesion components and total lesion volumes were automatically calculated by the software. Lesion burdens were calculated as total lesion volume/total lung volume × 100%. The attenuation of lesion components was defined as the mean attenuation in HUs of the total lesion volume.

Statistical analysis

Data were tested for normality with Shapiro–Wilks test. Categorical variables were expressed as absolute numbers and percentages and continuous variables were expressed as mean ± standard deviation or median with interquartile range (IQR), as appropriate. Univariate comparisons were done with $\chi^2$ or Fisher’s exact tests and continuous variables were compared using Student’s $t$-test or Wilcoxon-Mann–Whitney rank-sum test, as appropriate. In order to assess the associations of clinical factors and type of SARS-CoV-2 lineage with CT-derived pneumonia
severity, uni- and multivariate linear regression analyses were performed. As established by the prior studies, the following clinical predictors were entered into multivariate model: age, sex, BMI, hypertension, diabetes mellitus, hyperlipidemia, smoking status, history of chronic lung disease, heart failure, myocardial infarction, coronary artery revascularization, chronic kidney disease, immunodeficiency, serum C-reactive protein level and type of SARS-CoV-2 lineage (B.1.1.7 or non-B.1.1.7). A two-sided p-value < .05 was considered statistically significant. All analyses were performed using R (v. 4.0.2).

Role of the funding source
The funding source had no influence on study design, on the collection, analysis, and interpretation of data, on the writing of the manuscript, or on the decision to submit the paper for publication.

RESULTS
Demographic and baseline clinical data
Altogether 1000 patients (500 with B.1.1.7 and 500 with non-B.1.1.7 infection) were included in our analysis. Flowchart of patient inclusion can be seen in Figure 1. Patients with B.1.1.7 were younger (58.5 ± 15.6 years vs 64.8 ± 17.3 years; p < .001) and had less comorbidities such as hypertension (53.9% vs 66.7%; p < .001), diabetes mellitus (21.1% vs 28.7%; p = .007), hyperlipidemia (9.3% vs 18.5%; p < .001), lung disease (7.8% vs 14.5%; p = .001), heart failure (8.5% vs 13.7%; p = .011), myocardial infarction (3.6% vs 7.5%; p = .012), chronic kidney disease (3.8% vs 11.9%; p < .001) and immunodeficiency (8.2% vs 18.6%; p < .001). There was no difference in the duration of symptoms to the time of chest-CT (7 days [IQR: 4–7 days] vs 6 days [IQR: 4–8 days]; p = .817). Patients with B.1.1.7 had a significantly greater number of symptoms such as fever (66.7% vs 43.7%; p < .001), dyspnea (54.0% vs 38.6%; p < .001), dry cough (55.4% vs 40.0%; p < .001) and hemoptostis (4.2% vs 0.8%; p = .001), while those with non-B.1.1.7 infection had greater number of cases with sputum production (5.4% vs 10.0%; p = .011), loss of smell (2.4% vs 8.1%; p < .001), loss of taste (2.8% vs 8.3%; p < .001) and muscle and/or joint pain (7.7% vs 12.6%; p = .014). Regarding the laboratory parameters patients with B.1.1.7 variant had significantly higher levels of C-reactive protein (89.4 mg l−1 [36.5–146.1 mg l−1] vs 60.7 mg l−1 [15.6–123.0 mg l−1]; p < .001). Detailed data on demographic and baseline clinical parameters are reported in Table 1.

Chest-CT findings
The prevalence of GGO and consolidation was similar between the two groups, while pleural effusion was more common in patients with non-B.1.1.7 infection (7.6% vs 24.2%; p < .001). Bilateral pneumonia was more common in B.1.1.7 patients (96.8% vs 91.2%; p < .001). Regarding the lobar distribution, pneumonia was depicted more often in each of the five lung lobes in B.1.1.7 infection with the biggest differences in the right upper (96.2% vs 88.4%; p < .001), right medial (92.6% vs 77.4%; p < .001) and left upper (95.2% vs 87.0%; p < .001) lobes. Accordingly, pneumonia affecting all five lung lobes was more common in patients with B.1.1.7 lineage (90.8% vs 71.2%; p < .001).

Patients with B.1.1.7 infection had higher total lesion burden (16.1% [IQR: 6.0–34.2%] vs 6.6% [IQR: 1.2–18.3%]; p < .001) and GGO burden (14.2 [5.5–32.6%] vs 3.9% [IQR: 0.6–12.6%; p < .001). The mean attenuation of total lung lesion (−451.8 ± 177.6 HU vs −482.8 ± 119.0 HU; p = .001) and GGO (−511.9 ± 88.3 HU vs −532.5 ± 90.8 HU; p = .001) and consolidation (−124.7 ± 89.9 HU vs −147.3 ± 115.4 HU; p = .002) were higher in infections caused by the B.1.1.7 lineage. Detailed results on the chest-CT findings can be seen in Supplementary Table 1.
Table 1. Demographic, baseline clinical and laboratory data

|                              | Second wave (n = 500) | Third wave (n = 500) | p     |
|------------------------------|-----------------------|----------------------|-------|
| Age (years)                  | 64.8 ± 17.3           | 58.5 ± 15.6          | <.001 |
| Male sex, n (%)              | 268 (53.6)            | 287 (57.5)           | .237  |
| Body mass index (kg/m²)      | 29.0 ± 6.4            | 30.8 ± 6.1           | .020  |
| Hypertension, n (%)          | 330 (66.7)            | 268 (53.9)           | <.001 |
| Diabetes mellitus, n (%)     | 142 (28.7)            | 105 (21.1)           | .007  |
| Hyperlipidemia, n (%)        | 91 (18.5)             | 46 (9.3)             | <.001 |
| Smoking ever, n (%) (n = 301, 248) | 101 (33.6)          | 74 (29.8)            | .402  |
| History of lung disease, n (%) | 72 (14.5)            | 39 (7.8)             | .001  |
| History of heart failure, n (%) | 68 (13.7)            | 42 (8.5)             | .011  |
| History of myocardial infarction, n (%) | 37 (7.5)            | 18 (3.6)             | .012  |
| Chronic kidney disease, n (%) | 59 (11.9)            | 19 (3.8)             | <.001 |
| Immunodeficiency, n (%)      | 92 (18.6)             | 41 (8.2)             | <.001 |
| Onset of symptoms to chest-CT (days) | 6 (4–8)               | 7 (4–7)              | .817  |
| Fever, n (%)                 | 216 (43.7)            | 331 (66.7)           | <.001 |
| Chills, n (%)                | 13 (2.6)              | 21 (4.2)             | .231  |
| Fatigue, n (%)               | 140 (28.5)            | 156 (31.5)           | .338  |
| Dyspnea, n (%)               | 190 (38.6)            | 268 (54.0)           | <.001 |
| Dry cough, n (%)             | 197 (40.0)            | 275 (55.4)           | <.001 |
| Sputum production, n (%)     | 49 (10.0)             | 27 (5.4)             | .011  |
| Hemoptosis, (%)              | 4 (0.8)               | 21 (4.2)             | .001  |
| Sore throat, n (%)           | 16 (3.3)              | 18 (3.6)             | .880  |
| Loss of smell, n (%)         | 40 (8.1)              | 12 (2.4)             | <.001 |
| Loss of taste, n (%)         | 41 (8.3)              | 14 (2.8)             | <.001 |
| Muscle or joint pain, n (%)  | 62 (12.6)             | 38 (7.7)             | .014  |
| Nausea, vomiting, n (%)      | 56 (11.4)             | 45 (9.1)             | .274  |
| Diarrhea, n (%)              | 46 (9.3)              | 46 (9.3)             | 1.000 |
| Lymphopenia, n (%)           | 203 (40.9)            | 273 (54.8)           | <.001 |
| Lymphocytes, % (n = 495, 495) | 17.6 (11.7–26.0)     | 15.6 (10.6–21.5)    | .304  |
| LDH, U/L (n = 416, 400)      | 255.5 (190.0–346.0)   | 378.5 (287.8–517.0) | <.001 |
| C-reactive protein, mg/L (n = 492, 496) | 60.7 (15.6–123.0) | 89.4 (36.5–146.1)  | <.001 |
| Ferritin, ng/mL (n = 406, 356) | 464.5 (233.0–901.0)  | 946.0 (474.8–1563.5) | <.001 |
| Prothrombin time, sec (n = 370, 352) | 9.0 (8.5–9.9)   | 8.8 (8.3–9.4)       | <.001 |
| D-dimer, mg/mL (n = 364, 335) | 1.1 (0.6–2.6)        | 1.0 (0.6–1.6)       | .126  |
| Troponin, ng/L (n = 350, 376) | 16.0 (8.0–37.8)      | 11.0 (8.0–23.0)     | <.001 |
| Creatine phosphokinase, U/L (n = 319, 349) | 84.0 (36.5–178.5)  | 162.0 (85.0–384.0) | <.001 |
| WHO Category                 |                       |                      |       |
| Mild                         | 49 (9.8)              | 58 (11.6)            | .015  |
| Moderate                     | 307 (61.4)            | 304 (60.8)           |       |
| Severe                       | 25 (5.0)              | 46 (9.2)             |       |
| Death                        | 119 (23.8)            | 92 (18.4)            |       |

LDH, lactate dehydrogenase; WHO, World Health Organization.
Age-specific differences in the radio-morphological features and severity of pneumonia

To examine the variant-specific differences in severity as stratified by age, we divided the patients into three age groups: <60 years (n = 423; 61.5% with B.1.1.7), 60–75 years (n = 314; 48.4% with B.1.1.7) and >75 years (n = 263; 33.5% with B.1.1.7). Regarding the prevalence of lung abnormalities, we found differences between the two lineages only among younger patients (<60 years). In this group, GGO without consolidation was more common in patients with non-B.1.1.7 infection (26.5% vs 38.7%; p = .012), while GGO and consolidation was more prevalent in those with B.1.1.7 (70.4% vs 50.9%; p < .001). Pleural effusion was more common in non-B.1.1.7 infection in all three age groups. Bilateral pneumonia was more common in B.1.1.7 infection across the age groups, but the difference proved to be statistically significant only in patients <60 years (94.6% vs 79.1%; p < .001). As for lobar involvement, pneumonia affecting all five lung lobes was more prevalent in patients under 75 years with B.1.1.7 (86.9% vs 57.7% in patients <60 years and 96.7 vs 77.2% in those between 60 and 75 years; both p < .001), while in the oldest patient group the difference was not significant.

Quantitative lung features also differed significantly across the age groups. While total lesion burden (14.7% [IQR: 5.5–32.0%] vs 3.1% [IQR: 0.2–14.2%] in patients <60 years, 18.9% [IQR: 7.2–37.0%] vs 7.7% [IQR: 1.8–18.0%] in patients 60–75 years and 17.4% [6.0–35.6%] vs 8.9% [IQR: 2.4–21.7%]; all p < .001) and GGO burden (13.9% [IQR: 5.4–30.4%] vs 2.6% [IQR: 0.1–8.9%] in patients <60 years, 15.7% [IQR: 6.3–35.7%] vs 4.8% [IQR: 0.8–11.9%] in patients 60–75 years and 12.7% [IQR: 5.2–32.9%] vs 4.5% [IQR: 1.2–14.8%] in those >75 years; all p < .001) were significantly higher in B.1.1.7 pneumonia in all three age groups, consolidation burden significantly differed only in those patients <60 years (0.1% [IQR: 0.0–0.7%] vs 0.1% [IQR:0.0–0.2%]; p < .001). The mean attenuation of total lung lesion (−482.4 ± 102.6 HU vs −492.5 ± 160.9 HU; p = .041) and GGO (−502.0 ± 83.8 HU vs −541.4 ± 103.8 HU; p < .001) were significantly higher in B.1.1.7 pneumonia, but only in those <60 years. Representative cases of CT findings are shown in Figure 2. Detailed data on CT parameters of non-B.1.1.7 and B.1.1.7 pneumonia across the age groups are reported in Table 2 and Figure 3.

We also examined if the type of lineage was significantly associated with the pneumonia burden. In the univariate analysis, B.1.1.7 variant of concern was linked with higher total lung lesion burden in all three age groups (β: 12.6% [95%CI: 8.9–16.3%] in patients <60 years, β: 9.5% [95%CI: 5.2–13.8%] in patients 60–75 years and β: 8.1% [95%CI: 3.2–12.9%] in those >75 years; all p < .05). After adjustment for baseline demographic and clinical data, B.1.1.7 lineage was significantly associated with increased pneumonia burden only in patients <60 years [β: 15.0% (95%CI: 6.7–23.4%); p < .001]. Results of the uni- and multivariate linear regression analyses can be seen in Table 3.

Clinical severity

Mortality rate was similar in all age groups (9.6% vs 9.8% in patients <60 years; 19.1 vs 23.5% in those 60–75 years and 43.2 vs 37.1% in patients >70 years; all p > .05). When comparing the clinical severity of COVID-19 between the two lineages, we have observed differences only in patients <60 years, where B.1.1.7 variant of concern was linked to a lower proportion of mild (17.3% vs 25.8%; p = .048) and a higher proportion of severe disease (11.5% vs 4.9%; p = .032). In the other two age groups, there were no differences in the severity of illness between the lineages. Data on the age-specific outcome stratified by type of SARS-CoV-2 variant can be seen in Table 4 and Figure 4.

DISCUSSION

In our study population of 1000 COVID-19 patients (50% with B.1.1.7 infection), B.1.1.7 infection was not associated with increased risk of death as compared to the non-B.1.1.7 infection. However, B.1.1.7 was associated with increased total pneumonia burden and GGO burden, and higher lung lesion attenuation as compared to non-B.1.1.7 lineage. Moreover, in patients <60 years, those with B.1.1.7 pneumonia had increased consolidation burden, and severe COVID-19 was more prevalent. The B.1.1.7 lineage was an independent predictor of pneumonia burden only in patients < 60 years of age.
Table 2. Characteristics and quantitative measures of lung lesions, as stratified by age

| Lung abnormality | <60 years (n = 423) | 60–75 years (n = 314) | <75 years (n = 263) | p | Non-B.1.1.7 (n = 163) | B.1.1.7 (n = 260) | Non-B.1.1.7 (n = 162) | B.1.1.7 (n = 152) | Non-B.1.1.7 (n = 175) | B.1.1.7 (n = 88) | p |
|------------------|---------------------|-----------------------|---------------------|---|----------------------|------------------|----------------------|------------------|----------------------|------------------|---|
| Only ground-glass opacities, n (%) | 63 (38.7) | 69 (26.5) | .012 | 54 (33.3) | 52 (34.2) | .964 | 35 (20.0) | 17 (19.3) | 1.000 |
| Only consolidation, n (%) | 1 (0.6) | 0 (0.0) | .814 | 1 (0.6) | 0 (0.0) | 1.000 | 35 (20.0) | 17 (19.3) | 1.000 |
| Ground-glass opacities and consolidation, n (%) | 83 (50.9) | 183 (70.4) | <.001 | 106 (65.4) | 99 (65.1) | 1.000 | 139 (79.4) | 70 (79.5) | 1.000 |
| Pleural effusion, n (%) | 17 (10.4) | 10 (3.8) | .013 | 44 (27.2) | 13 (8.5) | <.001 | 60 (34.3) | 15 (17.0) | .005 |
| None, n (%) | 14 (8.6) | 7 (2.7) | .007 | 1 (0.6) | 1 (0.6) | 1.000 | 1 (0.6) | 1 (1.1) | 1.000 |
| Laterality | | | | | | | | | | | |
| Unilateral, n (%) | 20 (12.3) | 7 (2.7) | <.001 | 6 (3.7) | 0 (0.0) | .047 | 2 (1.1) | 0 (0.0) | .799 |
| Only right, n (%) | 13 (8.0) | 5 (1.9) | .006 | 4 (2.5) | 0 (0.0) | .148 | 1 (0.6) | 0 (0.0) | 1.000 |
| Only left, n (%) | 7 (4.3) | 2 (0.8) | .036 | 2 (1.2) | 0 (0.0) | .506 | 1 (0.6) | 0 (0.0) | 1.000 |
| Bilateral, n (%) | 129 (79.1) | 246 (94.6) | <.001 | 155 (95.7) | 151 (99.3) | .089 | 172 (98.3) | 87 (98.9) | 1.000 |
| Lobar distribution | | | | | | | | | | | |
| Right upper lobe, n (%) | 125 (76.7) | 244 (93.8) | <.001 | 148 (91.4) | 151 (99.3) | .002 | 169 (96.6) | 86 (97.7) | .893 |
| Right middle lobe, n (%) | 104 (63.8) | 229 (88.1) | <.001 | 136 (84.0) | 148 (97.4) | <.001 | 147 (84.0) | 86 (97.7) | .002 |
| Right lower lobe, n (%) | 137 (84.0) | 250 (96.2) | <.001 | 155 (95.7) | 151 (99.3) | .089 | 170 (97.1) | 87 (98.9) | .657 |
| Left upper lobe, n (%) | 120 (73.6) | 244 (93.8) | <.001 | 149 (92.0) | 149 (98.0) | .029 | 166 (94.9) | 83 (94.3) | 1.000 |
| Left lower lobe, n (%) | 134 (82.2) | 247 (95.0) | <.001 | 155 (95.7) | 151 (99.3) | .089 | 167 (95.4) | 85 (96.6) | .906 |
| Lobar involvement | | | | | | | | | | | |

(Continued)
### Table 2. (Continued)

|                      | <60 years (n = 423) |         | 60–75 years (n = 314) |         | <75 years (n = 263) |         |
|----------------------|---------------------|---------|-----------------------|---------|---------------------|---------|
|                      | Non-B.1.1.7 (n = 163) | B.1.1.7 (n = 260) | p         | Non-B.1.1.7 (n = 162) | B.1.1.7 (n = 152) | p         |
| One lobe, n (%)      | 14 (8.6)            | 2 (0.7) | <.001                 | 3 (1.9)  | 0 (0.0)             | <.001   |
| Two lobes, n (%)     | 16 (9.8)            | 5 (1.9) | <.001                 | 4 (2.5)  | 0 (0.0)             | 1 (0.6) | 0 (0.0) |
| Three lobes, n (%)   | 8 (4.9)             | 8 (3.1) | <.001                 | 13 (8.0) | 1 (0.7)             | 6 (3.4) | 2 (2.3) |
| Four lobes, n (%)    | 20 (12.3)           | 12 (4.6) | <.001                 | 17 (10.5) | 3 (2.0)          | 28 (16.0) | 4 (4.5) |
| Five lobes, n (%)    | 94 (57.7)           | 226 (86.9) | <.001                 | 125 (77.2) | 147 (96.7) | 137 (78.3) | 81 (92.0) |

#### Lung lesion volume (ml)

|                      | <60 years (n = 423) |         | 60–75 years (n = 314) |         | <75 years (n = 263) |         |
|----------------------|---------------------|---------|-----------------------|---------|---------------------|---------|
| Total                | 107.9 (4.4–493.4)   | 526.8 (219.3–1110.5) | <.001 | 307.8 (61.5–673.6)   | 715.3 (294.1–1459.6) | <.001 |
| Ground-glass opacities | 92.0 (3.0–345.1)   | 490.5 (202.5–1049.7) | <.001 | 216.4 (34.6–488.4)   | 654.2 (248.6–1378.6) | <.001 |
| Consolidation        | 0.2 (0.0–6.3)       | 2.5 (0.1–26.2)       | <.001 | 3.4 (0.0–23.7)       | 1.9 (0.1–18.3)       | .740  |
| Effusion             | 0.0 (0.0–0.0)       | 0.0 (0.0–0.0)        | .006  | 0.0 (0.0–21.4)       | 0.0 (0.0–0.0)        | <.001 |

#### Lungs lesion burden (%)

|                      | <60 years (n = 423) |         | 60–75 years (n = 314) |         | <75 years (n = 263) |         |
|----------------------|---------------------|---------|-----------------------|---------|---------------------|---------|
| Total                | 3.1 (0.2–14.2)      | 14.7 (5.5–32.0) | <.001 | 7.7 (1.8–18.0)      | 18.9 (7.2–37.0)      | <.001 |
| Ground-glass opacities | 2.6 (0.1–8.9)       | 13.9 (5.4–30.4) | <.001 | 4.8 (0.8–11.9)      | 15.7 (6.3–35.7)      | <.001 |
| Consolidation        | 0.1 (0.0–0.2)       | 0.1 (0.0–0.7)     | <.001 | 0.1 (0.0–0.6)       | 0.1 (0.0–0.5)        | .524  |
| Effusion             | 0.0 (0.0–0.0)       | 0.0 (0.0–0.0)     | .006  | 0.0 (0.0–0.6)       | 0.0 (0.0–0.0)        | <.001 |

#### Lungs lesion mean attenuation (HU)

|                      | <60 years (n = 423) |         | 60–75 years (n = 314) |         | <75 years (n = 263) |         |
|----------------------|---------------------|---------|-----------------------|---------|---------------------|---------|
| Total                | −492.5 ± 160.9      | −482.4 ± 102.6 | .041   | −449.7 ± 184.9      | −500.0 ± 128.3      | .062  |
| Ground-glass opacities | −541.4 ± 103.8      | −502.0 ± 83.8 | <.001 | −536.1 ± 83.2       | −531.3 ± 91.3       | .969  |
| Consolidation        | −152.7 ± 132.3      | −115.6 ± 85.3 | .117  | −149.0 ± 104.6      | −144.8 ± 99.2       | .686  |
| Effusion             | −22.6 ± 34.6        | −15.9 ± 21.7 | .712  | −30.9 ± 36.7        | −23.1 ± 29.3        | .645  |
Previous studies have reported that B.1.1.7 is more transmissible, as compared to other variants. However, results on the effect of this variant of concern on the severity of COVID-19 are less certain and the majority of these datasets do not include detailed data on the potential confounders and mediators of clinical outcome. In our study, granular patient data have been collected including demographic, baseline clinical, and laboratory values. Previous studies have shown that B.1.1.7 variant was associated with increased mortality. However, these studies were based on a community-based database and failed to report disease severity, while another study of 341 patients (58% with B.1.1.7 infection) reported similar disease severity and clinical outcomes between non-B.1.1.7 and B.1.1.7 infections after adjustment for age, sex, ethnicity, and comorbidities. Our results are in line with these latter conclusions in the overall population, however in younger patients (<60 years) B.1.1.7 lineage was associated with more severe COVID-19 with a similar mortality rate as the non-B.1.1.7 infection. This might be partly due to the advanced patient management over time and partly due to patient characteristics, as prevalence and number of comorbidities are strongly associated with age. Interestingly, while vaccination was not available during the first study period (non-B.1.1.7 patients), in those with B.1.1.7 infection 14 patients had previously had at least one shot of

Table 3. Association between type of SARS-CoV-2 variant and total lung lesion burden, as stratified by age

| Outcome: total lung lesion burden (%) | <60 years (n = 423) | 60–75 years (n = 314) | <75 years (n = 263) |
|-------------------------------------|---------------------|-----------------------|---------------------|
|                                     | ß (95% CI)          | p                    | ß (95% CI)          | p                    | ß (95% CI)          | p                    |
| Unadjusted                          | Non-B.1.1.7 lineage | Ref                  | ...                 | Ref                  | ...                 | Ref                  |
|                                     | B.1.1.7 lineage     | 12.6 (8.9–16.3)      | <.001               | 9.5 (5.2–13.8)       | <.001               | 8.1 (3.2–12.9)       | .001                 |
| Adjusted                            | Non-B.1.1.7 lineage | Ref                  | ...                 | Ref                  | ...                 | Ref                  |
|                                     | B.1.1.7 lineage     | 15.0 (6.7–23.4)      | <.001               | 8.1 (-0.25–16.5)     | .057                | -0.47 (-12.5–11.6)   | .938                 |

BMI, body mass index.

*Adjusted for sex, BMI, hypertension, diabetes mellitus, hyperlipidemia, smoking status, history of chronic lung disease, heart failure, myocardial infarction, chronic kidney disease, immunodeficiency and serum C-reactive protein level.
vaccination (4 in the <60 years, 4 in the 60–75 years, and 6 in the >75 years age group). These observations are in line with the European Centre for Disease Prevention and Control statistics, as less than 10 per 100 people were fully vaccinated in the age group above 60 years and less than 5 per 100 people have received both vaccine shots in the <60 years age group in Hungary as of March 1, 2021.13

Based on previous reports, CT is an important diagnostic tool in patients with suspected COVID-19 and combining its results with clinical and laboratory parameters could facilitate timely patient management.14–18 COVID-19 pneumonia manifests, even in asymptomatic patients, with rapid evolution from unilateral to bilateral GGO representing the early exudative phase within the first 5 days from the onset of symptoms followed by consolidative changes in the intraalveolar space with fibroblast proliferation and collapse of the alveoli within 1–3 weeks.17,19 Accordingly, the presence of consolidation has been shown to be independently associated with more severe disease and adverse outcomes.12,20 In our study population, however, B.1.1.7 higher total pneumonia burden was driven by increased GGO burden, as compared to non-B.1.1.7 infection.

Given recent development in the application of artificial intelligence in medical imaging, deep-learning-based approaches offer a great promise for the precise detection and prognostication of COVID-19, and several different methods have been reported recently.21–24

However, as of the date of this writing, no robust study on the characteristics of B.1.1.7 pneumonia evaluated from chest-CT has been reported. Here, we demonstrate distinct quantitative tomographic measures present in patients infected with B.1.1.7 VOC as assessed with the deep-learning algorithm. To our knowledge, this is the first study to investigate the radio-morphological differences between B.1.1.7 and non-B.1.1.7 infections, as quantified by a deep-learning-based algorithm in a large study population of 1000 patients (50% with B.1.1.7 infection). Moreover, detailed clinical data including demographic and laboratory parameters and comorbidities were collected in all patients. Clinical severity was graded according to the clinical progression scale of the WHO. Age-specific subanalyses were done to further investigate the differences between the two lineages. There are some limitations to be acknowledged. First, during the third wave (B.1.1.7 infections), the less severe cases might have been treated at home, and hospital admissions may have represented a more severe patient population. This might have introduced a selection bias. However, it is important to note that the admission criteria of patients with suspected COVID-19 did not change in the third wave as compared to the second wave in our country. Second, we did not analyze the progress of pneumonia during an in-hospital stay. However, the main purpose of this analysis was to study the differences between the two lineage infections. Moreover, the effect of therapy on the outcomes was not studied. Nonetheless, standard supportive care was applied with only a minority receiving targeted intervention.

COVID-19 is still a major global health problem and new SARS-CoV-2 variants raise public health concerns. Our study provides data on deep-learning-based quantitative lung lesion burden and clinical outcomes of patients infected by B.1.1.7 VOC. Our results, in combination with further studies on the effect of vaccination on the new variants are essential for the public health interventions in the COVID-19 pandemic. Our findings might serve as a model for later investigations, as new variants are emerging across the globe.

**CONFLICT OF INTEREST STATEMENT**

No conflict of interest

**Table 4. Age-specific severity of COVID-19 as stratified by type of SARS-CoV-2 lineage**

| Age Group | Non-B.1.1.7 (n = 163) | B.1.1.7 (n = 260) | p  |
|-----------|----------------------|------------------|----|
| <60 years | Mild disease, n (%)  | 42 (25.8)        | 45 (17.3)     | .037 |
|           | Moderate disease, n (%) | 97 (59.5)        | 160 (61.5)    |     |
|           | Severe disease, n (%) | 8 (4.9)          | 30 (11.5)     |     |
|           | Death, n (%)          | 16 (9.8)         | 25 (9.6)      |     |
| 60–75 years | Mild disease, n (%)  | 6 (3.7)          | 10 (6.6)      | .453 |
|           | Moderate disease, n (%) | 109 (67.3)       | 101 (66.4)    |     |
|           | Severe disease, n (%) | 9 (5.5)          | 12 (7.9)      |     |
|           | Death, n (%)          | 38 (23.5)        | 29 (19.1)     |     |
| >75 years | Mild disease, n (%)  | 1 (0.6)          | 3 (3.4)       | .214 |
|           | Moderate disease, n (%) | 101 (57.7)       | 43 (48.9)     |     |
|           | Severe disease, n (%) | 8 (4.6)          | 4 (4.5)       |     |
|           | Death, n (%)          | 65 (37.1)        | 38 (43.2)     |     |

Figure 4. COVID-19 severity across age groups and by SARS-CoV2 lineage type.
REFERENCES

1. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-cov-2 lineage B.1.1.7 in England. Science 2021; 372(6538): eabg3055. https://doi.org/10.1126/science.abg3055

2. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic characteristics and clinical effect of the emergent SARS-cov-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis 2021; 21: 1246–56. https://doi.org/10.1016/S1473-3099(21)00170-5

3. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsinetra-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-cov-2 variant of concern 202012/1: matched cohort study. BMJ 2021; 372: 579. https://doi.org/10.1136/bmj.n579

4. Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, et al. Case fatality risk of the SARS-cov-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill 2021; 26: 11. https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256

5. Kim H. Outbreak of novel coronavirus (COVID-19): what is the role of radiologists? Eur Radiol 2020; 30: 3266–67. https://doi.org/10.1007/s00330-020-06748-2

6. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: A longitudinal study. Radiology 2020; 296: E55–64. https://doi.org/10.1148/radiol.202000843

7. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. AJR Am J Roentgenol 2020; 214: 1280–86. https://doi.org/10.2214/AJR.20.22954

8. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295: 715–21. https://doi.org/10.1148/radiol.2020200370

9. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020; 295(3): 200463. https://doi.org/10.1148/radiol.2020200463

10. Characterisation WHO GotC, Management of C-1. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192–97. https://doi.org/10.1016/S1473-3099(20)30483-7

11. Grodecki K, Killekar A, Lin A, Cadet S, McElhinney P, Razipour A, et al. Rapid quantification of COVID-19 pneumonia burden from computed tomography with convolutional LSTM networks. ArXiv 2021; arXiv:2104.00138v1.

12. Grodecki K, Lin A, Cadet S, McElhinney PA, Razipour A, Chan C, et al. Quantitative burden of COVID-19 pneumonia on chest CT predicts adverse outcomes: A post-hoc analysis of A prospective international registry. Radiol Cardiothorac Imaging 2020; 2: e200389. https://doi.org/10.1148/ryct.2020200389

13. Available from: https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea

14. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the coronavirus disease (COVID-19): rrt-PCR or CT? Eur J Radiol 2020; 126: 108961. https://doi.org/10.1016/j.ejrad.2020.108961

15. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiol 2020; 296: E115–17. https://doi.org/10.1148/rg.2020200432

16. Sperrin M, Grant SW, Peek N. Prediction models for diagnosis and prognosis in covid-19. BMJ 2020; 369: m1464. https://doi.org/10.1136/bmj.m1464

17. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in wuhan, china: a descriptive study. Lancet Infect Dis 2020; 20: 425–34. https://doi.org/10.1016/S1473-3099(20)30086-4

18. Lucatelli P, Del Monte M, De Rubeis G, Cundari G, Francone M, Panebianco V, et al. Did we turn a blind eye? the answer is simply there. peripheral pulmonary vascular thrombosis in COVID-19 patients explains sudden worsening of clinical conditions. Imaging 2020; 12: 4–7. https://doi.org/10.1556/1647.2020.00002

19. Tian S, Xuong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsys. Med Pathol 2020; 33: 1007–14. https://doi.org/10.1038/s41379-020-0536-x

20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: a retrospective cohort study. Lancet 2020; 395: 1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3

21. Wang L, Lin ZQ, Wong A. COVID-19: a tailored deep convolutional neural network design for detection of COVID-19 cases from chest X-ray images. Sci Rep 2020; 10(1): 19549. https://doi.org/10.1038/s41598-020-76550-z

22. Wang S, Kang B, Ma J, Zeng X, Xiao M, Guo J, et al. A deep learning algorithm using CT images to screen for corona virus disease (COVID-19). Eur Radiol 2021; 31: 6096–6104. https://doi.org/10.1007/s00330-021-07715-1

23. Wang S, Zha Y, Li W, Wu Q, Li X, Niu M, et al. A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis. Eur Respir J 2020; 56(2): 2000775. https://doi.org/10.1183/13993003.00775-2020

24. Ardakani AA, Kanafi AR, Acharya UR, Khadem N, Mohammadi A. Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: results of 10 convolutional neural networks. Comput Biol Med 2020; 121: 103795. https://doi.org/10.1016/j.compbiomed.2020.103795